Secretome Therapy Shows Promise for Healing Craniofacial Bone Fractures
Background
Craniofacial fractures, injuries to the face and skull, often require complex interventions for proper healing and functional restoration. Current treatments can be invasive or have limitations in promoting optimal bone regeneration. This systematic review addresses the knowledge gap regarding the efficacy of secretome therapy in enhancing craniofacial bone healing in both animal and human models.
Why It Matters
This comprehensive review highlights the significant potential of secretome therapy as an innovative approach for treating craniofacial fractures. By naturally boosting the production of critical bone-repairing substances like VEGF, IGF, and BMP2, secretome therapy could offer a more effective and biologically integrated solution for patients. This could lead to novel clinical applications for accelerating bone regeneration and improving patient outcomes in craniofacial surgery. Further extensive research, particularly larger-scale human trials (e.g., Phase II/III clinical trials), is warranted to confirm these promising findings and establish standardized protocols.